Humacyte (NASDAQ:HUMA - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.07, Zacks reports. The firm had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million.
Humacyte Stock Performance
HUMA stock traded down $0.15 during midday trading on Tuesday, hitting $1.56. 6,029,444 shares of the company's stock were exchanged, compared to its average volume of 3,376,224. Humacyte has a one year low of $1.55 and a one year high of $9.97. The company has a market cap of $195.71 million, a PE ratio of -1.16 and a beta of 1.36. The stock's fifty day moving average price is $3.56 and its 200-day moving average price is $4.47.
Wall Street Analyst Weigh In
HUMA has been the topic of several analyst reports. Benchmark restated a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Humacyte in a research note on Wednesday, March 12th. Finally, D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $13.71.
Read Our Latest Analysis on HUMA
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
